Imugene doses first patient in Moldova with cancer vaccine

Company News

by Rachael Jones

Immuno-oncology company Imugene (ASX:IMU) has dosed the first patient in Moldova in Eastern Europe for the treatment of HER-2 positive gastric cancer.

It's an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine.

HER-Vaxx is a potentially groundbreaking cancer vaccine designed to produce an antibody response against a cancer growth signal receptor protein called HER-2 which is found on the cell surface of multiple cancers including breast and gastic cancers.

The start of the Phase 2 study is an important milestone for Imugene and the many medical professionals seeking treatments for patients with advanced HER-2 positive gastric cancer who often have very few medical options.

The Phase 1b HER-Vaxx study reported no safety or toxicity issues. All evaluable patients showed increased antibody responses.

One patient saw a complete response, five had a partial response and four recorded a stabilisation of their disease.

Shares in Imugene (ASX:IMU) Opened flat at 2 cents.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.